XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2025
Stock-Based Compensation  
Schedule of the Company's option activity

Weighted-

Weighted-

Average

Average

Remaining

Aggregate

    

    

Exercise

    

Contractual

    

Intrinsic

Price Per

Term

Value

Options

Share

(in years)

(in thousands)

Outstanding as of December 31, 2024

 

7,670,908

$

9.59

 

8.2

$

1,777

Stock options assumed in connection with the ACELYRIN Merger

4,712,186

$

12.99

Granted

 

6,983,120

$

4.60

Exercised

 

$

$

Forfeited or expired

 

(956,679)

$

9.07

Outstanding, vested and expected to vest as of September 30, 2025

 

18,409,535

$

8.60

7.0

$

388

Exercisable as of September 30, 2025

10,661,758

$

10.66

5.2

$

116

    

    

    

Weighted-

    

Weighted-

Average

Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

Price Per

Term

Value

Options

Share

(in years)

(in thousands)

Outstanding as of December 31, 2024

 

1,787,880

$

10.19

 

9.3

$

Granted

 

$

 

 

  

Forfeited or expired

 

(107,056)

$

10.19

 

 

Outstanding, vested and expected to vest as of September 30, 2025

 

1,680,824

$

10.19

 

8.6

$

Exercisable as of September 30, 2025

 

$

 

$

Schedule of various significant assumptions used to estimate the fair value of stock options

Nine Months Ended September 30, 

    

2025

    

2024

Expected term (in years)

5.23 - 6.08

 

5.75 - 6.08

Volatility

98.84% - 104.32%

 

103.65% - 109.54%

Risk-free interest rate

3.69% - 4.65%

 

3.47% - 4.48%

Dividend yield

0.00%

0.00%

Schedule of activity for the Company's early exercisable shares

Weighted-

Average

Number of

Exercise Price

    

Shares

    

Per Share

Unvested as of December 31, 2024

 

146,683

$

5.53

Vested

 

(125,805)

$

4.96

Unvested as of September 30, 2025

 

20,878

$

8.96

schedule of estimating the fair value of the stock purchase rights under the ESPP

Nine Months Ended

    

September 30, 2025

Expected term (in years)

0.32 - 0.50

Volatility

79.42% - 133.00%

Risk-free interest rate

4.25% - 4.33%

Dividend yield

0.00%

Schedule of unvested RSU activity

Weighted-

Average

Grant Date

Number of

Fair Value

    

Shares

    

Per Share

RSUs assumed in connection with the ACELYRIN Merger

 

1,470,868

$

13.46

RSUs granted

 

2,449,945

$

3.95

RSUs released

(1,115,413)

$

13.76

RSUs forfeited

 

(134,495)

$

5.48

Unvested as of September 30, 2025

 

2,670,905

$

5.01

Schedule of the stock-based compensation expense

The following table summarizes the stock-based compensation expense recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2025

    

2024

    

2025

    

2024

Research and development

$

5,773

$

3,720

$

16,717

$

6,805

General and administrative

 

4,014

3,589

18,700

6,294

Total stock-based compensation expense

$

9,787

$

7,309

$

35,417

$

13,099

The following table summarizes the stock-based compensation expense recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss by award type for the three and nine months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2025

    

2024

    

2025

    

2024

Stock options

$

7,979

$

7,291

$

28,771

$

13,045

RSUs

1,542

5,939

ESPP

266

701

Restricted stock awards

 

18

6

54

Total stock-based compensation expense

$

9,787

$

7,309

$

35,417

$

13,099